Patient Leaflet Updated 14-Oct-2024 | Gilead Sciences Ltd
Trodelvy 180 mg powder for concentrate for solution for infusion
Trodelvy 180 mg powder for concentrate for solution for infusion
sacituzumab govitecan
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side affects you may get. See the end of section 4 for how to report side effects.
1. What Trodelvy is and what it is used for
2. What you need to know before you are given Trodelvy
3. How you will be given Trodelvy
4. Possible side effects
5. How to store Trodelvy
6. Contents of the pack and other information
Trodelvy is a cancer medicine that contains the active substance sacituzumab govitecan.
Trodelvy is used to treat a type of breast cancer in adults called triple-negative breast cancer (TNBC). Trodelvy should only be used after patients have tried at least two other treatments for their cancer, including at least one of them for a locally advanced cancer or metastasised cancer.
Trodelvy is used to treat a type of breast cancer in adults called hormone receptor -positive (HR+), human epidermal growth factor receptor 2 -negative (HER2-) breast cancer. Trodelvy should only be used after patients have tried a treatment including a hormonal anticancer treatment and at least two additional other treatments for a locally advanced cancer or metastasised cancer.
Talk to your doctor or nurse if you have any questions about how Trodelvy works or why this medicine has been prescribed for you.
You must not be given Trodelvy if you are allergic to sacituzumab govitecan, to any of the other ingredients of this medicine (listed in section 6), or if you are allergic to irinotecan. If you think you may be allergic, ask your doctor for advice.
Seek urgent medical attention if you notice any of the following serious side effects whilst being given or after you are given Trodelvy:
Neutropenia
This is a condition where you have too few neutrophils in your blood after receiving Trodelvy, resulting in increased risk of infections. These infections can be severe, life-threatening and may lead to death. Seek urgent medical attention if you have the following signs and symptoms that may be due to having too few neutrophils (including infections):
Your doctor will take blood samples to monitor neutrophils. You will not be given Trodelvy if the absolute neutrophil count is below a certain level on Day 1 or Day 8 of any cycle.
Your doctor will adjust the amount of medicine you are given if you have severe neutropenia.
Fever
Seek urgent medical attention if you have the following signs and symptoms:
Diarrhoea
Seek urgent medical attention if you suffer from severe diarrhoea, whilst receiving Trodelvy (for example, black or bloody stools; symptoms of dehydration such as lightheadedness, dizziness, or faintness; inability to take fluids by mouth due to nausea or vomiting; or inability to get diarrhoea under control within 24 hours).
Contact your doctor or nurse the first time that you get diarrhoea. Your Trodelvy treatment will be postponed until your diarrhoea has improved.
You will be given loperamide to treat your diarrhoea, as long as you do not have an infection. If appropriate, you may also be given fluids into your veins (intravenously). Your doctor may also give you medicine, such as atropine, to help with stomach cramps, diarrhoea, and excessive saliva in mouth before your next treatment infusion. Your diarrhoea can lead to dehydration and sudden kidney damage. Talk to your doctor if you experience dark-coloured urine or decreased urine volume.
Allergic and Infusion related reactions (reactions related to your infusion of the medicine)
These reactions can be severe and life-threatening and can emerge when receiving Trodelvy. Seek urgent medical attention if you have the following signs and symptoms of allergic and infusion related reactions:
You may be given some medicine before Trodelvy is administered to help relieve the symptoms. During each infusion of Trodelvy and for 30 minutes after, you will be closely monitored for these signs and symptoms of infusion-related reactions. Your doctor will slow down the infusion rate or stop it if you develop a serious infusion-related reaction.
Please let your doctor, pharmacist or nurse know if you have previously experienced any problems after receiving infusions, such as dizziness, feeling of fainting, difficulty breathing, breathlessness, swelling or skin rash, swelling of your face, lips, tongue, or throat, chills or shaking chills (rigors), and fever.
Nausea and vomiting
Seek urgent medical attention if you suffer from uncontrolled nausea or vomiting whilst receiving Trodelvy.
Your doctor will give you anti-sickness medicines before and after Trodelvy is administered to help relieve nausea and vomiting. You will not be given Trodelvy if you have severe nausea and vomiting and will only be given Trodelvy when the symptoms have been controlled.
Some patients are genetically more likely to have certain side effects from Trodelvy. If you have the UGT1A1*28 gene, you are more likely to develop low white blood cell count (neutropenia), a fever while your white blood cell count is low, low level of red blood cell count (anaemia). You may also be more likely to develop other side effects after being given Trodelvy than those who do not have the gene.
See section 4. for a list of all the side effects related to Trodelvy.
Trodelvy must not be given to children under 18 years of age because there is no information about its use in this age group.
Tell your doctor if you are taking, have recently taken or might take any other medicines, including herbal medicines while receiving Trodelvy. This is because Trodelvy or the other medicines may not work as well as expected or you may be more likely to get a side effect.
This includes in particular:
Tell your doctor immediately if you are pregnant, think you may be pregnant or are planning to have a baby. Trodelvy must not be given if you are pregnant.
Women must use effective contraception during treatment with Trodelvy, and for 6 months after the last dose of Trodelvy.
Men with female partners who can become pregnant must use effective contraception during treatment and for 3 months after the last dose of Trodelvy.
Do not breast-feed during treatment with Trodelvy and for 1 month after the last dose. It is unknown whether this medicine passes into breast milk.
You may experience side effects of Trodelvy that may affect your ability to drive and use machines. You should therefore be cautious when driving, using tools or operating machines after being given Trodelvy.
Trodelvy will only be given to you by your doctor or a nurse experienced in using anti-cancer therapies.
It is important that the doctor specialising in your care has confirmed you can take this medicine by carrying out a blood test prior to treatment.
Medicines given before Trodelvy treatment
You will be given some medicines before receiving Trodelvy to help with side effects, such as nausea and vomiting and influsion-related reactions.
How much you will be given
The dose you are given will depend on your weight. Your doctor will weigh you and will determine the dose you should receive.
Frequency of administration
You should usually receive Trodelvy twice every 3 weeks on Days 1 and 8 of a 21- day treatment cycle.
How you will be given your medicine
A doctor or nurse will put the medicine into your bloodstream via an intravenous infusion (a drip into your vein).
First infusion: you will be given your first infusion of Trodelvy over 3 hours. Your doctor or nurse will monitor you for signs and symptoms of infusion-related reactions both during the infusion and 30 minutes after.
Second and subsequent infusions: you will be given the other infusions over 1 to 2 hours, if your first infusion was uneventful. Your doctor or nurse will monitor you during and 30 minutes after your infusion.
Infusion-related reactions
Your doctor will slow down the infusion rate of Trodelvy if you develop an infusion-related reaction. The medicine will be stopped if the infusion reaction is life-threatening. See section 2.
Dose of medicine when experiencing some side-effects
Your doctor may adjust the dose or stop Trodelvy if you experience certain side effects. See section 4.
Since the infusion is given to you by your doctor or other appropriately trained staff, an overdose is unlikely. If you inadvertently receive too much medicine, your doctor will monitor you and give you additional supportive care to prevent and treat side effects.
If you forget or miss your appointment, contact your doctor or your treatment centre to make another appointment as soon as possible.
You should not stop the therapy early without talking with your doctor first.
The therapy for breast cancer with Trodelvy usually requires a number of treatments. The number of infusions that you receive will depend on how you are responding to treatment. Therefore, you should continue to take Trodelvy even if you see your symptoms improve until your doctor recommends that Trodelvy should be stopped.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Seek urgent medical attention if you get any of the following serious side effects:
Very common
(may affect more than 1 in 10 people)
Common
(may affect up to 1 in 10 people)
Other side effects are listed below. If any of these become severe or serious, tell your doctor immediately.
Very common
(may affect more than 1 in 10 people)
Common
(may affect up to 1 in 10 people)
Uncommon
(may affect up to 1 in 100 people)
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the vial label and carton after EXP. The expiry date refers to the last day of that month that the medicine can be used.
Store in a refrigerator (2°C to 8°C). Do not freeze.
Keep the vial in the outer carton in order to protect from light.
Once reconstituted, the infusion bag containing Trodelvy solution can be stored in a refrigerator at 2°C to 8°C for up to 24 hours protected from light.
Do not use this medicine if you notice the reconstituted solution is cloudy or discoloured.
Trodelvy is a cytotoxic drug. Applicable special handling and disposal procedures must be followed.
Do not throw away any medicines via wastewater. The hospital pharmacist will throw away medicines you no longer use. These measures will help protect the environment.
The medicine is an off-white to yellowish powder. It comes as 50 mL clear glass single-dose vials, with a rubber stopper and crimp-sealed with an aluminum flip-off cap. Each pack contains 1 vial.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
This leaflet was last revised in August 2024.
Other sources of information
Detailed information on this medicine is available on the website of the Medicines and Healthcare Regulatory Agency (MHRA) https://www.gov.uk/guidance/find-product-information-about-medicines and other websites https://www.medicines.org.uk/emc/.
280 High Holborn, London, WC1V 7EE, UK
+44 (0)203 681 4681
08000 113 700 (UK)
+44 (0)203 681 4500
+353 1 291 3580 (Ireland)
+353 214 825 999 (Ireland)